Capecitabine in combination with novel targeted agents in the management of metastatic breast cancer: Underlying rationale and results of clinical trials

Oncologist

Volumn 12, Issue 4, 2007, Pages 375-389

  Tripathy, Debu ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b Physicians' Education Resource   (United States)

Author keywords

Antineoplastic agents; Biological response modifiers; Breast neoplasm; Capecitabine

Indexed keywords

ANTHRACYCLINE; BEVACIZUMAB; BORTEZOMIB; CAPECITABINE; CELECOXIB; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXIFLURIDINE; DOXORUBICIN; EPIRUBICIN; EPOTHILONE DERIVATIVE; FLUOROURACIL; GEMCITABINE; GTI 2040; IMATINIB; INDISULAM; ISPINESIB; IXABEPILONE; LAPATINIB; MITOMYCIN C; NAVELBINE; PACLITAXEL; PEGINTERFERON; PLACEBO; SULINDAC SULFONE; TAMOXIFEN; THALIDOMIDE; TIPIFARNIB; TRASTUZUMAB;

ANEMIA; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DIARRHEA; DRUG ANTAGONISM; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG RESPONSE; DRUG TOLERABILITY; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; LEUKOPENIA; LOADING DRUG DOSE; MONOTHERAPY; MOTOR DYSFUNCTION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROPATHY; NONHUMAN; PAIN; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; REVIEW; THROMBOCYTOPENIA;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL RESPONSE MODIFIERS; BREAST NEOPLASMS; CLINICAL TRIALS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; NEOPLASM METASTASIS;

EID: 34247885996     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.12-4-375     Document Type: Review

References (103)

1. National Cancer Institute. Surveillance Epidemiology and End Results. Available at http://seer.cancer.gov/csr/1975_2003/results_single/sect_01_table. 01.pdf. Accessed May 17, 2006.
2. O'Shaughnessy J. Extending survival with chemotherapy in metastatic breast cancer. The Oncologist 2005;10(suppl 3):20-29.
3. Chia SKL, Speers C, Kang A et al. The impact of new chemotherapeutic and hormonal agents on the survival of women with metastatic breast cancer (MBC) in a population based cohort. Proc Am Soc Clin Oncol 2003; 22:22. Available at http://www.asco.org/portal/site/ASCO/menuitem.34 d60f5624ba07fd506fe310ee37a01d/ ?vgnextoid= 76f8201eb61a7010V gnVCM100000ed730ad1RCRD&vmview= abst_detail_view&confID =23&abstractID=101414. Accessed May 16, 2006.
4. Giordano SH, Buzdar AU, Smith TL et al. Is breast cancer survival improving? Cancer 2004;100:44-52.
5. Abrial C, Leheurteur M, CabrespineAet al. Does survival increase in metastatic breast cancer with recently available anticancer drugs? Oncol Res 2006;15:431-439.
6. Fossati R, Confalonieri C, TorriVet al. Cytotoxic and hormonal treatment for metastatic breast cancer: A systematic review of published randomized trials involving 31,510 women. J Clin Oncol 1998;16:3439-3460.
7. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that over-expresses HER2. N Engl J Med 2001;344:783-792.
8. Albain KS, Nag S, Calderillo-Ruiz G et al. Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): First report of overall survival. J Clin Oncol 2004;22(suppl 14):510.
9. O'Shaughnessy J, Miles D, Vukelja S et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol 2002;20:2812-2823.
10. Ershler WB. Capecitabine monotherapy: Safe and effective treatment for metastatic breast cancer. The Oncologist 2006;11:325-335.
11. Xeloda® [package insert]. Nutley, NJ: Roche Laboratories Inc, 2005.
12. Smith DB, Neoptolemos JP. Capecitabine in carcinoma of the pancreas. Expert Opin Pharmacother 2006;7:1633-1639.
13. Longley DB, Harkin DP, Johnston PG. 5-Fluorouracil: Mechanisms of action and clinical strategies. Nat Rev Cancer 2003;3:330-338.
14. Soong R, Diasio RB. Advances and challenges in fluoropyrimidine pharmacogenomics and pharmacogenetics. Pharmacogenomics 2005;6:835-847.
15. Walko CM, Lindley C. Capecitabine: A review. Clin Ther 2005;27:23-44.
16. Sawada N, Ishikawa T, Fukase Y et al. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by Taxol/Taxotere in human cancer xenografts. Clin Cancer Res 1998;4:1013-1019.
17. Sawada N, Ishikawa T, Sekiguchi F et al. X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts. Clin Cancer Res 1999;5:2948-2953.
18. Endo M, Shinbori N, Fukase Y et al. Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5′-deoxy-5- fluorouridine by cyclophosphamide in mammary tumor models. Int J Cancer 1999;83:127-134.
19. Toi M, Bando H, Horiguchi S et al. Modulation of thymidine phosphorylase by neoadjuvant chemotherapy in primary breast cancer. Br J Cancer 2004;90:2338-2343.
20. Li Y, Hussain M, Sarkar SH et al. Gene expression profiling revealed novel mechanism of action of Taxotere and furtulon in prostate cancer cells. BMC Cancer 2005;5:7.
21. von Minckwitz G, Blohmer JU, Loehr A. Comparison of docetaxel/ doxorubicin/cyclophosphamide (TAC) versus vinorelbine/capecitabine (NX) in patients non-responding to 2 cycles of neoadjuvant TAC chemotherapy - first results of the phase III GEPARTRIO - Study by the German Breast Group. Breast Cancer Res Treat 2005;94(suppl 1):38a. Available at http://209.196.53.174/2005. Accessed May 16, 2006.
22. Lee KS, Lee ES, Kwon YM et al. Mature results from a randomized phase III trial of docetaxel/capecitabine (TX) vs. doxorubicin/cyclophosphamide (AC) as primary chemotherapy for patients with stage II/III breast cancer. Breast Cancer Res Treat 2005:94(suppl 1):5052a.
23. Mavroudis D, Boukovinas I, Ardavanis A. A multicenter phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first line treatment in patients with locally advanced and metastatic breast cancer. Preliminary report. Breast Cancer Res Treat 2005;94(suppl 1):6084a.
24. Chan S, Romieu G, Huober J et al. Gemcitabine plus docetaxel (GD) versus capecitabine plus docetaxel (CD) for anthracycline-pretreated metastatic breast cancer (MBC) patients (pts): Results of a European phase III study. J Clin Oncol 2005:23(suppl 16):581. Available at http://www.asco.org/portal/site/ASCO/ menuitem.d3934b88626d03a781d54d10ee 37a01d/?vgnextoid= 8a7ca1f903878010VgnVCM100000f2730ad1R CRD&spk=Chan%2C Stephen %5Bfau%5D&epdAbst=N&epdV M=Y&epdJCO=N&epdPubMed=N&epdEdBook= N&index=n. Accessed May 20, 2006.
25. Lueck H, von Minckwitz G, Du BoisAet al. Epirubicin/paclitaxel (EP) vs. capecitabine/paclitaxel (XP) in first-line metastatic breast cancer (MBC): A prospective, randomized multicentre phase III study of the AGO breast cancer study group. J Clin Oncol 2006:24(suppl 18):517. Available at http://www.asco.org/portal/site/ASCO/menuitem.64cfbd0f85cb37b2 eda2be0aee37a01d/?vgnextoid=09f8201eb61a7010VgnVCM100000 ed730ad1RCRD& vmview=vm_search_results_view&selectedConfs=40&SearchFilter= Speaker&SearchTerm=lueck. Accessed July 20, 2006.
26. Soto C, Torrecillas L, Reyes S et al. Capecitabine (X) and taxanes in patients (pts) with anthracycline-pretreated metastatic breast cancer (MBC): Sequential vs. combined therapy results from a MOSG randomized phase III trial. J Clin Oncol 2006;24(suppl 18):570.
27. Beslija S, Obralic N, Basic H et al. Randomized trial of sequence vs. combination of capecitabine (X) and docetaxel (T): XT vs. T followed by X after progression as first-line therapy for patients (pts) with metastatic breast cancer (MBC). J Clin Oncol 2006;24(suppl 18):571.
28. Miller KD, Chap LI, Holmes FA et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005;23:792-799.
29. Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355:2733-2743.
30. Wardley A, Antón-Torres A, Pivot X et al. Trastuzumab plus docetaxel with or without capecitabine in patients with HER2-positive advanced/metastatic breast cancer: First efficacy results from the Phase II MO16419 (CHAT) study. Breast Cancer Res Treat 2006;100(suppl 1):2063a.
31. Schaller G, Bangemann N, Weber J et al. Efficacy and safety of trastuzumab plus capecitabine in a German multicentre phase II study of pretreated metastatic breast cancer. J Clin Oncol 2005;23:(16S)717.
32. Schaller G, Bangemann N, Gonsch T et al. Capecitabine and trastuzumab: A phase II study in HER2-overexpressing metastatic breast cancer (MBC) patients pretreated with anthracyclines and/or taxanes. Breast Cancer Res Treat 2005;94(suppl 1):2033a.
33. Yamamoto D, Iwase S, Kitamura K et al. Multicenter phase II study of trastuzumab (H) and capecitabine (X) as first- or second-line treatment in HER2 over-expressing metastatic breast cancer (Japan Breast Cancer Study Group: JBCSG-003). J Clin Oncol 2005;23(suppl 16):802.
34. Xu L, Song S, Zhu J et al. Capecitabine (X) trastuzumab (H) as first-line treatment in patients (pts) with HER2-positive metastatic breast cancer (MBC): Phase II trial results. Breast Cancer Res Treat 2006;100(suppl 1):2065a.
35. Chew HK, Barlow W, Albain K et al. SWOG 0338: A phase II trial of imatinib mesylate in combination with capecitabine in metastatic breast cancer. J Clin Oncol 2006;24(suppl 18):10529.
36. Lybaert W, Wildiers H, Neven P et al. Multicenter phase II study of neoadjuvant capecitabine (X), docetaxel (T) - trastuzumab (H) for patients (pts) with locally advanced breast cancer (LABC): Preliminary safety and efficacy data. Breast Cancer Res Treat 2006;100(suppl 1):3070a.
37. st line metastatic breast cancer trial. Breast Cancer Res Treat 2006;100(suppl 1):2068a.
38. Perez EA, Hillman DW, Kugler JW et al. North Central Cancer Treatment Group (NCCTG) N0432: Phase II trial of docetaxel with capecitabine and bevacizumab as first line chemotherapy for patients with metastatic breast cancer. Breast Cancer Res Treat 2006;100(suppl 1):2069a.
39. Bunnell CA, Klimovsky J, Thomas E. Final efficacy results of a phase I/II trial of ixabepilone in combination with capecitabine in patients with metastatic breast cancer (MBC) previously treated with a taxane and an anthracycline. J Clin Oncol 2006;24(suppl 18):10511a.
40. Pusztai L, Zhen JH, Arun B et al. Phase I and II study of exisulind in combination with capecitabine in patients with metastatic breast cancer. J Clin Oncol 2003;21:3454-3461.
41. U.S. National Institutes of Health, Department of Health and Human Services. ClinicalTrials.gov. Available at http://www.clinicaltrials.gov. Accessed January 15, 2006.
42. Schmid P, Schippinger W, Kiewe P et al. Bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines. Breast Cancer Res Treat 2005;94(suppl 1):1085a.
43. Fabi A, Milella M, Malaguti P et al. Pilot study of capecitabine combined with celecoxib (CapCel) for the treatment of far advanced metastatic breast cancer (MBC) patients (pts). J Clin Oncol 2006;24(suppl 18):10680.
44. Calvo E, Chu Q, Til E et al. Phase I study of ispinesib in combination with capecitabine in patients with advanced solid tumors. Presented at the 2005 International Conference on Molecular Targets and Cancer Therapeutics, Philadelphia, PA, November 2005. Available at http://www.aacr.org/default.aspx? p=6362. Accessed July 20, 2006. 45 Fumoleau P, Cameron D. Future options with capecitabine (Xeloda) in (neo)adjuvant treatment of breast cancer. Semin Oncol 2004;31(suppl 10):45-50.
45. Gradishar WJ, Meza LA, Amin B et al. Capecitabine plus paclitaxel as front-line combination therapy for metastatic breast cancer: A multicenter phase II study. J Clin Oncol 2004;22:2321-2327.
46. Blum JL, Dees EC, Chacko A et al. Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer. J Clin Oncol 2006;24:4384-4390.
47. Maring JG, Groen HJ, Wachters FM et al. Genetic factors influencing pyrimidine-antagonist chemotherapy. Pharmacogenomics J 2005;5:226-243.
48. Pegram MD, Pietras R, Bajamonde A et al. Targeted therapy: Wave of the future. J Clin Oncol 2005;23:1776-1781.
49. Pegram M, Hsu S, Lewis G et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 1999;18:2241-2251.
50. Pegram MD, Konecny GE, O'Callaghan C et al. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 2004;96:739-749.
51. Pietras RJ, Pegram MD, Finn RS et al. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene 1998;17:2235-2249.
52. Fujimoto-Ouchi K, Sekiguchi F, Tanaka Y. Antitumor activity of combinations of anti-HER-2 antibody trastuzumab and oral fluoropyrimidines capecitabine/5′-dFUrd in human breast cancer models. Cancer Chemother Pharmacol 2002;49:211-216.
53. Jain RK. Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 2005;307:58-62.
54. Izumi Y, Xu L, di Tomaso E et al. Tumour biology: Herceptin acts as an anti-angiogenic cocktail. Nature 2002;416:279-280.
55. Konecny GE, Meng YG, Untch M et al. Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin Cancer Res 2004;10:1706-1716.
56. Weidner N, Semple JP, Welch WR et al. Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med 1991;324:1-8.
57. Weidner N, Folkman J, Pozza F et al. Tumor angiogenesis: A new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992;84:1875-1887.
58. Schneider BP, Miller KD. Angiogenesis of breast cancer. J Clin Oncol 2005;23:1782-1790.
59. Cobleigh MA, Langmuir VK, Sledge GW et al. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 2003;30(suppl 16):117-124.
60. Miller KD, Wang M, Gralow J et al. A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: A trial coordinated by the Eastern Cooperative Oncology Group (E2100). Breast Cancer Res Treat 2005; 94(suppl 1):3a. Available at http://209.196.53.174/2005/player/gs1_03.html. Accessed May 16, 2006.
61. Sledge GW Jr. What is targeted therapy? J Clin Oncol 2005;23:1614-1615.
62. Bates DO, Cui TG, Doughty JM et al. VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Res 2002;62:4123-4131.
63. Woolard J, Wang WY, Bevan HS et al. VEGF165b, an inhibitory vascular endothelial growth factor splice variant: Mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res 2004;64:7822-7835.
64. Varey AHR, Qiu Y, Dixon AR et al. Avastin binds pro-angiogenic VEGF165 and anti-angiogenic VEGF165b with similar affinities. Presented at the 2006 British Microcirculation Society Annual Meeting, Dundee, Scotland, April 10-11, 2006, Abstract EC22.
65. Relf M, LeJeune S, Scott PA et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 1997;57:963-969.
66. Nelson MH, Dolder CR. Lapatinib: A novel dual tyrosine kinase inhibitor with activity in solid tumors. Ann Pharmacother 2006;40:261-269.
67. Konecny GE, Pegram MD, Venkatesan N et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 2006;66:1630-1639.
68. Burris HA 3rd. Dual kinase inhibition in the treatment of breast cancer: Initial experience with the EGFR/ErbB-2 inhibitor lapatinib. The Oncologist 2004;9(suppl 3):10-15.
69. Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005;353:172-187.
70. Carvalho I, Milanezi F, Martins A et al. Overexpression of plateletderived growth factor receptor alpha in breast cancer is associated with tumour progression. Breast Cancer Res 2005;7:R788-795.
71. Diallo R, Rody A, Jackisch C et al. C-KIT expression in ductal carcinoma in situ of the breast: Co-expression with HER-2/neu. Hum Pathol 2006;37:205-211.
72. Modi S, Seidman AD, DicklerMet al.Aphase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer. Breast Cancer Res Treat 2005;90:157-163.
73. Head J, Johnston SR. New targets for therapy in breast cancer: Farnesyl-transferase inhibitors. Breast Cancer Res 2004;6:262-268.
74. Appels NM, Beijnen JH, Schellens JH. Development of farnesyl transferase inhibitors: A review. The Oncologist 2005;10:565-578.
75. Izbicka E, Campos D, CarrizalesGet al. Biomarkers of anticancer activity of R115777 (tipifarnib, Zarnestra) in human breast cancer models in vitro. Anticancer Res 2005;25:3215-3223.
76. Dalenc F, Giamarchi C, Petit M et al. Farnesyl-transferase inhibitor R115,777 enhances tamoxifen inhibition of MCF-7 cell growth through estrogen receptor dependent and independent pathways. Breast Cancer Res 2005;7:R1159-R1167.
77. Johnston SR, Hickish T, Ellis P et al. Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer. J Clin Oncol 2003;21:2492-2499.
78. Lebowitz PF, Eng-Wong J, Widemann BC et al. A phase I trial and pharmacokinetic study of tipifarnib, a farnesyltransferase inhibitor, and tamoxifen in metastatic breast cancer. Clin Cancer Res 2005;11:1247-1252.
79. Sparano JA, Moulder S, Kazi A et al. Targeted inhibition of farnesyltransferase in locally advanced breast cancer: A phase I and II trial of tipifarnib plus dose-dense doxorubicin and cyclophosphamide. J Clin Oncol 2006; 24:3013-3018.
80. Lee Y, Vassilakos A, Feng N et al. GTI-2040, an antisense agent targeting the small subunit component (R2) of human ribonucleotide reductase, shows potent antitumor activity against a variety of tumors. Cancer Res 2003;63:2802-2811.
81. Krepler C, Certa U, Wacheck V et al. Pegylated and conventional interferon-alpha induce comparable transcriptional responses and inhibition of tumor growth in a human melanoma SCID mouse xenotransplantation model. J Invest Dermatol 2004;123:664-669.
82. Certa U, Wilhelm-Seiler M, Foser S et al. Expression modes of interferonalpha inducible genes in sensitive and resistant human melanoma cells stimulated with regular and pegylated interferon-alpha. Gene 2003;315:79-86.
83. Talpaz M, Rakhit A, Rittweger K et al. Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia. Clin Cancer Res 2005;11:6247-6255.
84. Dummer R, Garbe C, Thompson JA et al. Randomized dose-escalation study evaluating peginterferon alfa-2a in patients with metastatic malignant melanoma. J Clin Oncol 2006;24:1188-1194.
85. Sakowicz R, Finer JT, Beraud C et al. Antitumor activity of a kinesin inhibitor. Cancer Res 2004;64:3276-3280.
86. Davis DA, Sarkar SH, Hussain M et al. Increased therapeutic potential of an experimental anti-mitotic inhibitor SB715992 by genistein in PC-3 human prostate cancer cell line. BMC Cancer 2006;6:22.
87. Richardson PG, Mitsiades C, Hideshima T et al. Bortezomib: Proteasome inhibition as an effective anticancer therapy. Annu Rev Med 2006;57:33-47.
88. Yang CH, Gonzalez-Angulo AM, Reuben JM et al. Bortezomib (VELCADE ®) in metastatic breast cancer: Pharmacodynamics, biological effects, and prediction of clinical benefits. Ann Oncol 2006;17:813-817.
89. Fukuoka K, Usuda J, Iwamoto Y et al. Mechanisms of action of the novel sulfonamide anticancer agent E7070 on cell cycle progression in human non-small cell lung cancer cells. Invest New Drugs 2001;19:219-227.
90. Abbate F, Casini A, Owa T et al. Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic isozymes I and II, and transmembrane, tumor-associated isozyme IX. Bioorg Med Chem Lett 2004;14:217-223.
91. Driessen A, Landuyt W, Pastorekova S et al. Expression of carbonic anhydrase IX (CA IX), a hypoxia-related protein, rather than vascularendothelial growth factor (VEGF), a pro-angiogenic factor, correlates with an extremely poor prognosis in esophageal and gastric adenocarcinomas. Ann Surg 2006;243:334-340.
92. Haapasalo JA, Nordfors KM, Hilvo M et al. Expression of carbonic anhydrase IX in astrocytic tumors predicts poor prognosis. Clin Cancer Res 2006;12:473-477.
93. Oratz R, Blum J, Rowland K et al. A phase II multicenter study of the cell cycle inhibitor indisulam in refractory metastatic breast carcinoma. J Clin Oncol 2005;23(suppl 16):685.
94. Gerth K, Bedorf N, Hofle G et al. Epothilones A and B: Antifungal and cytotoxic compounds from Sorangium cellulosum (Myxobacteria). Production, physico-chemical and biological properties. J Antibiot (Tokyo) 1996;49:560-563.
95. Goodin S, Kane MP, Rubin EH. Epothilones: Mechanism of action and biologic activity. J Clin Oncol 2004;22:2015-2025.
96. Klar U, Buchmann B, Schwede W et al. ZK-EPO, a novel epothilone derivative, exhibits significant tumor growth inhibition in a wide range of human tumor models. Presented at the 2005 International Conference on Molecular Targets and Cancer Therapeutics, Philadelphia, PA, November 2005. Available at http://www.aacr.org/default.aspx?p=6362. Accessed July 20, 2006.
97. Hoffmann J, Fichtner I, Käkönen S-M et al. ZK-EPO, a third generation epothilone, inhibits breast cancer metastasis. Proc Amer Assoc Cancer Res 2006;47:511.
98. Morgan GJ, Krishnan B, Jenner M et al. Advances in oral therapy for multiple myeloma. Lancet Oncol 2006;7:316-325.
99. Figg WD. The 2005 Leon I. Goldberg Young Investigator Award Lecture: Development of thalidomide as an angiogenesis inhibitor for the treatment of androgen-independent prostate cancer. Clin Pharmacol Ther 2006;79:1-8.
100. Baidas SM, Winer EP, Fleming GF et al. Phase II evaluation of thalidomide in patients with metastatic breast cancer. J Clin Oncol 2000;18:2710-2717.
101. Morabito A, Carillio G, Longo R et al. Thalidomide is inactive in heavily pretreated patients with metastatic breast cancer. Cancer J 2005;11:248-251.
102. Masferrer JL, Leahy KM, Koki AT et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000;60:1306-1311.
103. Harris RE, Beebe-Donk J, Alshafie GA. Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors. BMC Cancer 2006;6:27.